Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
Novel pseudomonas aeruginosa bacteriophage pse-aep-4 and use thereof for inhibiting proliferation of pseudomonas aeruginosa
US2019359949A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019359949-A1 |
| Application number | US-201816486595-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 11, 2018 |
| Priority date | Feb 17, 2017 |
| Publication date | Nov 28, 2019 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to Podoviridae bacteriophage Pse-AEP-4 (accession number: KCTC 13166BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-4 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-4 as an active ingredient.
First claim
Opening claim text (preview).
1 . A Podoviridae bacteriophage Pse-AEP-4 (Accession number: KCTC 13166BP) isolated from nature, which has an ability to specifically kill Pseudomonas aeruginosa and has a genome represented by SEQ ID NO: 1. 2 . A composition for preventing or treating a disease caused by Pseudomonas aeruginosa, comprising the bacteriophage Pse-AEP-4 (Accession number: KCTC 13166BP) of claim 1 as an active ingredient. 3 . The composition of claim 2 , provided in a form of a pharmaceutical composition further comprising a disinfectant and an antibiotic. 4 . A method of preventing or treating a disease caused by Pseudomonas aeruginosa, the method comprising: administering to an animal other than a human the composition of claim 2 . 5 . The method of claim 4 , wherein the composition is administered in a form of a pharmaceutical composition comprising a disinfectant and an antibiotic to the animal other than the human.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Antibacterial agents · CPC title
Viruses; Subviral particles; Bacteriophages · CPC title
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title
Demonstrated in vivo effect · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2019359949A1 cover?
- The present invention relates to Podoviridae bacteriophage Pse-AEP-4 (accession number: KCTC 13166BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-4 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing t…
- Who is the assignee on this patent?
- Intron Biotechnology Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Nov 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).